Flamen Patrick
Department of Nuclear Medicine, University Hospital Gasthuisberg, Leuven, Belgium.
Best Pract Res Clin Gastroenterol. 2002 Apr;16(2):237-51. doi: 10.1053/bega.2001.0283.
Positron emission tomography (PET) using (18)F-fluorodeoxyglucose (FDG) is increasingly used in the diagnostic management of colorectal cancer patients. It provides a highly sensitive and specific diagnosis which is entirely based upon alterations of the glucose metabolism found in malignant tissues. The information provided by FDG-PET is independent of the underlying structural characteristics of the lesions and, therefore, it is essentially complementary to the available structural imaging modalities such as CT, MRI and (endoscopic) ultrasound. Several studies have now been performed on the use of FDG-PET in colorectal adenocarcinoma for primary pre-operative staging, for diagnosis and (re)staging of recurrent disease, for localization and staging of occult recurrent disease, and for the assessment of the metabolic effects of chemotherapy and radiotherapy. This chapter aims to clarify some fundamental issues of both detection device and radiotracer, the proven indications for FDG-PET, the strength and limitations of the technique, and how its implementation would affect patient management.
使用（18）F-氟脱氧葡萄糖（FDG）的正电子发射断层扫描（PET）越来越多地用于结直肠癌患者的诊断管理。它提供了一种高度敏感和特异的诊断，完全基于在恶性组织中发现的葡萄糖代谢改变。FDG-PET提供的信息独立于病变的潜在结构特征，因此，它本质上是对CT、MRI和（内镜）超声等现有结构成像方式的补充。目前已经进行了多项关于FDG-PET在结直肠癌中的应用研究，包括用于原发性术前分期、复发性疾病的诊断和（再）分期、隐匿性复发性疾病的定位和分期，以及评估化疗和放疗的代谢效果。本章旨在阐明检测设备和放射性示踪剂的一些基本问题、FDG-PET已证实的适应症、该技术的优势和局限性，以及其实施将如何影响患者管理。
